0001103021-20-000081.txt : 20200512 0001103021-20-000081.hdr.sgml : 20200512 20200512184832 ACCESSION NUMBER: 0001103021-20-000081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200508 FILED AS OF DATE: 20200512 DATE AS OF CHANGE: 20200512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sirgo Mark A CENTRAL INDEX KEY: 0001301715 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 20870575 MAIL ADDRESS: STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL STREET 2: 801 CORPORATE CENTER DRIVE -SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 4 1 wf-form4_158932369364623.xml FORM 4 X0306 4 2020-05-08 0 0001103021 BIODELIVERY SCIENCES INTERNATIONAL INC BDSI 0001301715 Sirgo Mark A C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVENUE, SUITE 225 RALEIGH NC 27612 1 0 0 0 Common Stock 2020-05-08 4 S 0 100000 5.07 D 1264595 D Common Stock 2020-05-11 4 M 0 22500 0 A 1287095 D Restricted Stock Units 0.0 2020-05-11 4 M 0 22500 0 D 2020-05-11 2020-05-11 Common Stock 22500.0 0 D The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. On May 8, 2020, the Reporting Person sold an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.29 per share and the lowest sale price was $5.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. /s/ Mark A. Sirgo 2020-05-12